(NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback